Navigation Links
SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
Date:9/23/2009

NATICK, Mass. and SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.

The Company also announced that on October 1 it will begin its previously planned, phased discontinuation of the TAXUS Express Stent used in the SPIRIT IV trial. The TAXUS Express Stent has been replaced by the thinner-strut TAXUS((R)) Liberte((R)) Stent worldwide. The TAXUS Liberte Stent was approved in Europe in 2005, in the U.S. in 2008 and in Japan in 2009.

The SPIRIT IV results were presented at the 21(st) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium by Gregg W. Stone, M.D., Professor of Medicine and the Director of Research and Education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital, and Principal Investigator of the trial.

"We welcome the positive SPIRIT IV results reaffirming the safety and efficacy of our two drug-eluting stent platforms," said Donald S. Baim, M.D., Chief Medical and Scientific Officer at Boston Scientific. "The strong outcomes among diabetic patients treated with TAXUS Express were impressive, particularly the rates of target lesion failure (TLF) at one year, which were equivalent for PROMUS and TAXUS Express. These rates were actually lower for TAXUS Expr
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
4. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
5. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
6. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
7. Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Tests Impact on Weight Loss
8. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
9. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... , Dec. 23, 2014 PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced it ... MigraPure® H, a hemp-based, advanced headache relief product, for ... in Colorado , Washington ... With the MigraPure H Advanced headache relief ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... a clinical-stage company focused on commercialization of novel ... restatement of its exclusive international license agreement with ... technology related to monitoring drug therapy compliance.  The ... Sequella and UMB, addresses transdermal detection of a ...
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
Cached Medicine Technology:Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Researchers say they ... that develop into eggs and sperm. While this ... is the first time that these types of cells ... efficiently using human stem cells, according to the team ... creation of primordial germ cells is one of the ...
(Date:12/24/2014)... ladies, new fashionable outfits are necessary when heading into a ... Angeldress.co.uk has chosen some of their best dresses ... by launching a promotion on its cheap clothes and fashion ... off, like a cheap suit. , “All items are in ... are among the hottest items in the global market. They ...
(Date:12/24/2014)... Lauderdale, FL (PRWEB) December 24, 2014 There’s ... these days. With the Republican Party now in control of ... begins again for the Affordable Care Act. A lawsuit has ... that delays of certain provisions in the ACA have resulted ... (1) Also, a Supreme Court hearing will take place to ...
(Date:12/24/2014)... St. Louis, MO (PRWEB) December 24, 2014 ... Onder Law Firm announce an update to their website, ... information explains the difference between talcum powder class action ... provide weekly talcum powder and ovarian cancer updates at ... , “Talcum powder lawsuits for ovarian cancer claims are ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... hurt your child in the classroom, a new study finds. ... lagged behind by eighth grade, said researchers who reviewed questionnaires ... "The largest effects were found for the kids who reported ... assistant professor of human sciences at Ohio State University. "On ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:Can Fast Food Hinder Learning in Kids? 2
... W. M. Keck Foundation has awarded Arizona State University ... scientists led by Deirdre Meldrum, Ph.D., at the Biodesign ... three-dimensional (3D) imaging microscope, called a "Cell-CT" scanner, that ... living cells. This groundbreaking technology will allow researchers to ...
... help explain why African-Americans are twice as likely to be ... new study by Johns Hopkins researchers. The findings, if ... as easy as taking a cheap potassium supplement. ... taking potassium supplements," says Hsin-Chieh "Jessica" Yeh, Ph.D., an assistant ...
... , WEDNESDAY, March 2 (HealthDay News) -- Countering ... from mental illness, a new report says there,s actually no ... they often go without treatment that could prevent them from ... "pervasive, but mistaken, impression that young children do not develop ...
... HealthDay Reporter , TUESDAY, March 1 (HealthDay News) ... to increase the risk for breast cancer among postmenopausal ... found little or no connection between breast cancer and ... may be surfacing for the first time, experts noted. ...
... 18th Conference on Retroviruses and Opportunistic Infections is ... from February 27 through March 2. Day three of ... presentations from scientists supported by the National Institute of ... Institutes of Health. iPrEx Update , ...
... , Emory University experts predict that rates of depressive disorders ... In an editorial published in the March, 2011 issue of ... author Boadie Dunlop, MD, writes "Compared to women, many men ... protectors of their families. Failure to fulfill the role of ...
Cached Medicine News:Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 2Health News:$1 million from W.M. Keck Foundation spurs development of new generation 3-D 'Cell-CT' imaging 3Health News:Potassium levels possible key to racial disparity in Type 2 diabetes 2Health News:Even Tiny Tots May Develop Mental Health Problems 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 3Health News:CROI -- Day 3: Selected highlights of NIH-supported research 2Health News:Depressing future for men? 2
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... (E1) is one of the three major ... and estriol. Estrone is produced primarily from ... or gonads [1,2]. In premenopausal adult women, ... by the ovary. In prepubertal children, men ...
... most abundant circulating estrogen in non-pregnant women ... Sulfate is a major metabolite of estradiol ... in blood [2,3]. In premenopausal women, estrone ... and estradiol, rising gradually during the follicular ...
Medicine Products: